Cargando…

Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials

In Japan, the choice of anti-diabetic medication is officially recommended according to the patient’s glycemic condition and disease phenotype, unlike most other regions where metformin is recommended as the first-line medication. There has been an increase in the number of available glucose-lowerin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Atsushi, Node, Koichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394044/ https://www.ncbi.nlm.nih.gov/pubmed/30819188 http://dx.doi.org/10.1186/s12933-019-0834-0

Ejemplares similares

Cardiovascular surrogate markers and cardiometabolic therapeutics: a viewpoint learned from clinical trials on dipeptidyl peptidase-4 inhibitors
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Clinical application of glucagon-like peptide-1 receptor agonists in cardiovascular disease: lessons from recent clinical cardiovascular outcomes trials
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Clinical application of sodium-glucose cotransporter 2 inhibitor into a real-world setting of heart failure care
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

How should we monitor the cardiovascular benefit of sodium–glucose cotransporter 2 inhibition?
por: Tanaka, Atsushi, et al.
Publicado: (2020)

So‐far overlooked HFpEF patients with normal natriuretic peptide level need more evidence
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Using Evidence-Based Learning Strategies to Improve Medical Education
por: Madan, Christopher R.
Publicado: (2023)

Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Long-term observation of estimated fluid volume reduction after the initiation of ipragliflozin in patients with type 2 diabetes mellitus: a sub-analysis from a randomized controlled trial (PROTECT)
por: Tanaka, Atsushi, et al.
Publicado: (2023)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Effect of canagliflozin on white blood cell counts in patients with type 2 diabetes and heart failure: A subanalysis of the randomized CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
por: Booth, C M, et al.
Publicado: (2014)

Haemodynamic monitoring as an opportunity for tailoring diuretics and guideline‐directed medical therapy in heart failure
por: Malgie, Jishnu, et al.
Publicado: (2023)

Clinical trials in an Ebola outbreak seek to find an evidence-based cure
por: McMullan, Laura K.
Publicado: (2020)

The GSK-3β/Fyn/Nrf2 pathway in fibroblasts and wounds of type 2 diabetes: On the road to an evidence-based therapy of non-healing wounds
por: Bitar, Milad S.
Publicado: (2012)

Medical learning: From clinical-to-tech-based thinking (beyond typical clinical signs)
por: Mohammad, Ameen M.
Publicado: (2021)

Management of hyperglycemia in type 2 diabetes: evidence and uncertainty
por: Esposito, Katherine, et al.
Publicado: (2013)

Prediction of Stroke After Cardiac Catheterization: No Reason, No Stroke
por: Tanaka, Atsushi, et al.
Publicado: (2018)

Crosstalk between the liver and heart: revisited for prevention and treatment
por: Tanaka, Atsushi, et al.
Publicado: (2020)

The Emerging and Promising Role of Care for Cardiometabolic Syndrome in Prostate Cancer
por: Tanaka, Atsushi, et al.
Publicado: (2019)

In‐hospital therapy for worsening heart failure: black box or sweet spot?
por: Tanaka, Atsushi, et al.
Publicado: (2021)

Collective Knowledge Used to Unveil Cardiovascular Injury Emerged during COVID-19
por: Tanaka, Atsushi, et al.
Publicado: (2022)

What More Can Be Delivered to Future Patients with Coronary Syndromes?
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Comparing the Effects of Canagliflozin vs. Glimepiride by Body Mass Index in Patients with Type 2 Diabetes and Chronic Heart Failure: A Subanalysis of the CANDLE Trial
por: Sezai, Akira, et al.
Publicado: (2022)

Towards competency-based learning in medical education: Building evidence in India
por: Rege, N
Publicado: (2020)

Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’
por: Evans, Marc
Publicado: (2018)

Look Action for Health in Diabetes trial: What we have learned in terms of real world practice and clinical trials
por: Kwok, Ching-Fai, et al.
Publicado: (2014)

A Commentary on “Medical learning: From clinical-to-tech-based thinking (beyond typical clinical signs)”
por: Ascencio-Vera, María Gabriela, et al.
Publicado: (2021)

Effects of canagliflozin in patients with type 2 diabetes and chronic heart failure: a randomized trial (CANDLE)
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Clinical Effects of Topiroxostat on Renal and Endothelial Function in A Patient with Chronic Kidney Disease and Hyperuricemic Arteriolopathy: A Case Report
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Commentary: Treatment for Truncus Arteriosus Needs to Be Tailored
por: Lim, Hong-Gook
Publicado: (2023)

A roadmap to medical nutrition therapy in type 2 diabetes
por: Shalit, Almog, et al.
Publicado: (2023)

Tailoring interventions for social isolation among older persons during the COVID-19 pandemic: challenges and pathways to healthcare equity
por: Dassieu, Lise, et al.
Publicado: (2021)

The role of machine learning in clinical research: transforming the future of evidence generation
por: Weissler, E. Hope, et al.
Publicado: (2021)

To B or Not to B: (Anti)bodies of Evidence on the Crime Scene of Type 1 Diabetes?
por: Mallone, Roberto, et al.
Publicado: (2011)

Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
por: Kishimoto, Shinji, et al.
Publicado: (2023)

Pharmacoepigenetics in type 2 diabetes: is it clinically relevant?
por: Ling, Charlotte
Publicado: (2022)

Vascular functional tests and preemptive medicine
por: Tanaka, Atsushi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tdoc6autpurrmvt04dp9dc4mia